Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Phase Ib data released in July 2024 demonstrated a 7.3% reduction in body weight after 4 weeks of CT-996 treatment, versus 1.2% in placebo counterparts
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
We welcome research partners committed to improving outcomes through evidence-based nutraceutical and pharmaceutical strategies
EllieMD is not responsible for the accuracy or completeness of content shared by guests
US$ 26.87
US$ 28.50
US$ 20.92
US$ 22.62
US$ 21.57
US$ 25.81
